Safety and effectiveness of treatments that activate glucagon-like peptide-1 receptors in people with end-stage kidney disease

No systematic review and meta-analysis has analyzed the safety and efficacy of glucagon-like peptide-1 receptor agonism-based therapies in people with end-stage renal disease.

• Glucagon-like peptide-1 receptor agonism-based therapies may provide potential benefits for individuals with end-stage renal disease.
• The analysis addressed a significant gap in understanding the effects of these therapies on this patient population.
• End-stage renal disease is defined as a glomerular filtration rate less than 15 ml/min/1.73m² or the need for renal replacement therapy.

Simplified